UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 23, 2010

 

Abbott Laboratories

(Exact name of registrant as specified in its charter)

 

Illinois

 

1-2189

 

36-0698440

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification
No.)

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

 (Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (847) 937-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07               Submission of Matters to a Vote of Security Holders.

 

Abbott Laboratories held its Annual Meeting of Shareholders on April 23, 2010.  The following is a summary of the matters voted on at that meeting.

 

(a)         The shareholders elected Abbott’s entire Board of Directors.  The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and broker non-votes, with respect to each of these persons, were as follows:

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

Robert J. Alpern, M.D.

 

1,140,750,134

 

14,949,391

 

166,860,701

 

Roxanne S. Austin

 

1,123,409,954

 

32,289,571

 

166,860,701

 

William M. Daley

 

841,926,077

 

313,773,448

 

166,860,701

 

W. James Farrell

 

842,236,792

 

313,462,733

 

166,860,701

 

H. Laurance Fuller

 

838,528,414

 

317,171,111

 

166,860,701

 

William A. Osborn

 

841,918,166

 

313,781,359

 

166,860,701

 

The Rt. Hon. Lord Owen CH FRCP

 

1,129,504,665

 

26,194,860

 

166,860,701

 

Roy S. Roberts

 

1,133,957,595

 

21,741,930

 

166,860,701

 

Samuel C. Scott III

 

1,137,919,145

 

17,780,380

 

166,860,701

 

William D. Smithburg

 

837,639,004

 

318,060,521

 

166,860,701

 

Glenn F. Tilton

 

1,138,849,304

 

16,850,221

 

166,860,701

 

Miles D. White

 

1,119,364,303

 

36,335,222

 

166,860,701

 

 

(b)        The shareholders ratified the appointment of Deloitte & Touche LLP as Abbott’s auditors.  The number of shares cast in favor of the ratification of Deloitte & Touche LLP, the number against, the number abstaining, and broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

1,310,227,422

 

9,516,956

 

2,815,848

 

0

 

 

2



 

(c)         The shareholders rejected a shareholder proposal regarding an advisory vote on executive compensation. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

483,187,858

 

626,448,910

 

46,018,801

 

166,904,657

 

 

(d)        The shareholders rejected a shareholder proposal requesting the amendment of Abbott’s bylaws to allow holders of 10% of Abbott’s outstanding common shares to call a special shareholder meeting. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

442,598,695

 

703,426,759

 

9,673,491

 

166,861,281

 

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

 

 

Date: April 29, 2010

By:

/s/ Thomas C. Freyman

 

 

Thomas C. Freyman

 

 

Executive Vice President, Finance and Chief Financial Officer

 

4